MedTrace Logo

Bifidobacterium Lactis HN019 Supplementation for Prevention of Influenza Infection in Healthy Adults

NCT01258842 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 426

Last updated 2010-12-13

No results posted yet for this study

Summary

To determine if prophylactic supplementation with B. lactis HN019 reduces the risk of developing physician- and laboratory-confirmed influenza infection at any time during the 12-week supplementation period.

Conditions

Interventions

DIETARY_SUPPLEMENT

Bifidobacterium lactis HN019

B. lactis HN019 (5 billion cfu / day) sachet, consumed once per day for 12 weeks

DIETARY_SUPPLEMENT

Placebo

Placebo sachet, consumed once per day for 12 weeks

Sponsors & Collaborators

  • Danisco

    collaborator INDUSTRY

  • Sprim Advanced Life Sciences

    collaborator OTHER

  • Fonterra Research Centre

    lead INDUSTRY

Principal Investigators

  • Mario Clerici, MD · Milano University Medical School

  • Emilio Clementi · University of Milan

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-12-31
Primary Completion
2011-05-31
Completion
2011-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01258842 on ClinicalTrials.gov